Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
201.91
+0.28 (+0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
706,009
Open
201.99
Bid (Size)
201.00 (2)
Ask (Size)
201.91 (2)
Prev. Close
201.63
Today's Range
200.55 - 203.19
52wk Range
189.44 - 270.50
Shares Outstanding
144,000,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
August 11, 2024
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.
Via
The Motley Fool
Performance
YTD
-24.58%
-24.58%
1 Month
-10.82%
-10.82%
3 Month
-12.81%
-12.81%
6 Month
-7.89%
-7.89%
1 Year
-23.83%
-23.83%
More News
Read More
How Is The Market Feeling About Biogen?
August 09, 2024
Via
Benzinga
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
August 09, 2024
Via
FinancialNewsMedia
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biogen (BIIB) Q2 2024 Earnings Call Transcript
August 01, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales
August 01, 2024
Via
Benzinga
Biogen Earnings Flat; Biotech Giant Raises Guidance
August 01, 2024
Via
Investor's Business Daily
The Analyst Verdict: Biogen In The Eyes Of 12 Experts
July 29, 2024
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
August 01, 2024
Via
Benzinga
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)
July 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
August 01, 2024
Via
Benzinga
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
July 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
July 29, 2024
Via
The Motley Fool
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
July 26, 2024
Via
Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
July 26, 2024
Via
Investor's Business Daily
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024
From
Biogen Inc.
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
July 24, 2024
Via
Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
Via
Investor's Business Daily
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
July 24, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.